4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: GlobeNewswire
Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and transformative genetic medicinesProprietary intravitreal vector R100 demonstrated superior transduction and transgene expression compared to AAV2, the standard AAV serotypes used in retinal gene therapies, in all three human retinal cell types evaluated in vitro (up to ~10-fold improvement), and in all primate retinal cell layers after intravitreal injection in vivoIntravitreal administration of the R100 vector-based 4D-150 genetic medicine in nonhuman primate wet AMD model was well tolerated, led to robust retinal expression of dual transgenes (aflibercept and anti-VEGF C) and complete suppression of severe CNV choroidal neovascularization lesions4D-150 wet AMD (PRISM) and DME (SPECTRA) Phase 1/2 clinical trials are currently underway; 4FRONT Phase 3 program in wet AMD on target to initiate in
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Bank of America Co. from $79.00 to $46.00. They now have a "buy" rating on the stock.MarketBeat
- 4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS [Yahoo! Finance]Yahoo! Finance
- 4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]Yahoo! Finance
- 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Morgan Stanley. They set an "underweight" rating and a $8.00 price target on the stock.MarketBeat
- 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $39.00 price target on the stock.MarketBeat
FDMT
Earnings
- 11/13/24 - Miss
FDMT
Sec Filings
- 12/11/24 - Form 8-K
- 12/10/24 - Form 4
- 12/6/24 - Form SC
- FDMT's page on the SEC website